पोस्ट करनेवाले : stocktin
| Price when posted : BSE: Rs 473.90 ( 0.06 % ), NSE: Rs. 474.10 ( 0.13 % )|
akrmr,arrise,sanecounsel : I hv said it earlier too & I agree my view cd be flawed but for me syngene delisting is not such a grt deal.On the other hand listing of biocon research cd hv been .Syngene is a very predictable business & with or without biocon it can be valued rather easily.At best it can add abt 150 bucks to biocons valuations.Timing tht pop may be relevant for traders taking a fno position but not hugely material for long term investors of the stock..
The real value drivers in biocon r its r&d projects & God know wht is happening to them at least I dont.In feb presentation Mylan says they hall start phase 3 trials of glargine by first half of this yr & now we r in beginning of sept & yet no word on it.
Guys pl remember the cost of holding a 500 rs stock for a yr is abt 75 rs Whatever little shares I hv now left I am waiting for euphoria created by syngene or some outlicencing to get out
Guys there in another thing I realized after I decided to moove on all my bitterness and irritation just disappeared...